Status:
COMPLETED
Appropriate Inhaler Use of Tiotropium As Add-on Therapy in Symptomatic Asthma
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Asthma
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
This pragmatic, two-arm, randomized controlled trial study aim to survey the inhaler errors of add-on tiotropium therapy with ICS+LABA in real-world practice of asthma patients and the efficacy of rec...
Detailed Description
1. The clinical efficacy of tiotropium as add-on treatment to ICS with a LABA have been demonstrated in clinical trials in adult patients with symptomatic asthma. 2. Certain patients of daily care, li...
Eligibility Criteria
Inclusion
- Age 20 to 75 years old asthmatic patients under regular treatment
- Received medium to high dose ICS with LABA at least 3 months
- Persistent asthma related symptoms: asthma control questionnaire (ACQ-7\>1.5)
- Physicians in charged prescribed Tiotropium as add-on therapy according to clinical judgement.
Exclusion
- Refuse to provide inform consent
- Pregnancy or breastfeeding women
- Patients with chronic obstructive pulmonary disease
- Using other Long-acting Muscarinic Antagonists e.g. Sebree, Ultibro, Anoro and Spiolto
Key Trial Info
Start Date :
March 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04696965
Start Date
March 4 2021
End Date
November 20 2023
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Thoracic Medicine, Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 33305